

Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures

Yi Liu¹, Dalia Walzer², Sarah Schmitz¹, Alpana P. Shukla¹, Xiaoyue Ma³, Dawn Chirko², Ilissa Pipia², Swetha Sathi², Uthman Shukairy², Michael Greenberg², Sangeeta R. Kashyap¹, Emily M. Stein⁴

¹ Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, 10021

² Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, 10021

³ Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, 10021

⁴ Division of Endocrinology, Hospital for Special Surgery, New York, NY, 10021

Key word: semaglutide, tirzepatide, bone loss, osteoporosis, obesity, diabetes

Corresponding author:

Yi Liu, MD

yil9015@med.cornell.edu

Assistant Professor

Attending Physician

New York-Presbyterian/Weill Cornell Medical Center

Weill Cornell Medicine

Division of Endocrinology, Diabetes and Metabolism

1305 York Avenue

New York, NY 10021

T: 6469628690

ORCID#: 0009-0003-5448-3626

Reprint requests should be addressed to Dr. Yi Liu

Grants or fellowship: Not applicable

Disclosure summary: Alpana Shukla reports research funding from Eli Lilly and

Company and Novo Nordisk to their institution and serves on a paid advisory board for

Eli Lilly and Company. Emily M. Stein reports research funding from Radius and

Novartis. Yi Liu, Dalia Walzer, Sarah Schmitz, Xiaoyue Ma, Dawn Chirko, Ilissa Pipia,

Swetha Sathi, Uthman Shukairy, Michael Greenberg, Sangeeta Kashyap all report that

they have nothing to disclose.

1 **Abstract:**

2 **Context:** Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-
3 lowering and weight loss benefits, but their effects on bone remain unclear.

4 **Objective:** To investigate changes in bone mineral density (BMD) in patients using
5 semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1/glucose dependent
6 insulinotropic polypeptide.

7 **Methods:** Single-center retrospective study. Adult patients using SEM/TIR for ≥ 6
8 months with DXA scans before initiation and at least 6 months after were matched by
9 age, sex, BMI, and diabetes mellitus (DM) to non-users with at least two DXA scans
10 over the same period. The primary outcome was percentage change in total hip (TH)
11 BMD.

12 **Results:** We included 255 patients using SEM or TIR in the GLP-1 RA group (92%
13 female, mean age 64 ± 9 years, BMI 31.0 ± 5.6 kg/m²) and 255 controls. After a median
14 follow-up of 17 months, the GLP-1 RA group achieved median 5% weight loss. Both
15 groups had significant declines in BMD at TH and FN, with similar magnitude between
16 groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the
17 TH and FN ($r=0.32$ for TH, $r=0.17$ for FN, both $p<0.01$). Among patients without DM,
18 greater TH bone loss was noted in GLP-1 RA group compared to controls (-1% vs -
19 0.6%, $p=0.04$), whereas TH bone loss was similar between groups among patients with
20 DM.

21 **Conclusion:** SEM/TIR use was associated with greater annualized TH bone loss in
22 patients without DM, whereas TH bone loss was comparable between GLP-1 RA and

1 controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may
2 differ by DM status, with weight loss driving bone loss in patients without DM.

3 **Key word:** semaglutide, tirzepatide, bone loss, osteoporosis, obesity, diabetes

4 **Introduction:**

5 Obesity represents a growing global health challenge, imposing significant morbidity
6 and mortality as well as a substantial economic burden(1). The global prevalence of
7 obesity has increased dramatically from 8.8% in 1990 to 18.5% in 2022 among women
8 and from 4.8% to 14.0% among men(2). Currently, over one billion individuals
9 worldwide are affected by obesity, including 159 million children and adolescents and
10 879 million adults(2). In the United States, it is projected that one in two adults will have
11 obesity by 2030(3).

12 Incretins, including glucagon-like peptide 1 (GLP-1) and glucose-dependent
13 insulinotropic polypeptide (GIP), are hormones released by the gastrointestinal tract in
14 response to nutrient intake(4). Two newer incretin-based therapies—semaglutide, a
15 GLP-1 receptor agonist (GLP-1 RA), and tirzepatide, a dual GLP-1/GIP RA are being
16 increasingly prescribed for weight management due to their high efficacy(5). However,
17 despite their demonstrated effectiveness for weight loss and cardiometabolic benefits,
18 their impact on skeletal health remains largely uncertain.

19 Previous research has established that weight loss is associated with bone loss in
20 patients using caloric restriction and those who have undergone bariatric surgery (6,7).
21 While the underlying mechanisms remain unclear, they are likely multifactorial (6,8). As
22 GLP-1 RA can also produce significant weight loss, concerns have been raised about

1 whether they might negatively impact bone health. Several studies have investigated
2 the skeletal effects of earlier-generation GLP-1 RA and found no negative impact on
3 bone mineral density or fracture risk (9,10). However, these findings may be attributed
4 in part to the limited weight loss achieved with these agents (9,10). In contrast,
5 semaglutide and tirzepatide produce substantially greater weight loss compared to older
6 GLP-1 RA, raising questions about their potential musculoskeletal effects (11,12). For
7 example, a phase 2 trial by Hansen et al. reported that 52 weeks of semaglutide
8 treatment in patients without diabetes with osteopenia or prior fractures increased bone
9 resorption markers and reduced BMD at the lumbar spine, total hip, and tibia compared
10 with placebo(12). Given the increasing use of semaglutide and tirzepatide for weight
11 loss, it is important to evaluate the skeletal effects of these newer, more potent agents.

12 Importantly, diabetes mellitus (DM) represents a distinct clinical context in which
13 skeletal health and weight loss responses may differ(13,14). Both type 1 DM (T1DM)
14 and type 2 DM (T2DM) are associated with significantly increased fracture risk, though
15 through different pathophysiological mechanisms(13). While T1DM is typically
16 associated with reduced bone mineral density (BMD)(13,15), T2DM presents
17 paradoxically with preserved or elevated BMD but impaired bone quality compared to
18 the general population(16). Moreover, patients with DM generally experience less
19 weight loss in response to GLP-1 RA therapy compared with individuals without DM,
20 which may mitigate weight-loss–related bone loss(14). These differences suggest that
21 the skeletal effects of semaglutide and tirzepatide may not be uniform across DM and
22 non-DM populations and underscore the need for separate analyses based on DM
23 status.

1 Therefore, we conducted a study to elucidate the skeletal effects of semaglutide and
2 tirzepatide, aiming to fill the existing gap in knowledge regarding their impact on bone
3 health. We hypothesized that patients treated with semaglutide or tirzepatide would
4 experience greater bone loss compared with an age-, sex-, body mass index (BMI) and
5 DM-matched controls.

6 **Methods:**

7 *Patient population*

8 This retrospective study included adult patients who had two or more dual-energy X-ray
9 absorptiometry (DXA) scans at Weill Cornell Medical College between December 2017
10 and August 2024. Patients who initiated semaglutide or tirzepatide were included in the
11 GLP-1 RA group. Eligible patients had a baseline DXA within two years prior to
12 medication initiation and a follow-up DXA at least six months after starting therapy. The
13 maintenance dose was determined by the prescription with the largest number of
14 covered days filled during follow up periods. Maintenance doses of semaglutide 1.7 mg
15 or greater, and tirzepatide 10.0 mg or greater were considered high doses, with all other
16 doses categorized as low doses (17,18). Controls had at least two DXA scans within the
17 4 year period and no exposure to GLP-1 RA. The study was approved by the
18 Institutional Review Board of Weill Cornell Medical College.

19 *Statistical analysis*

20 Propensity score matching was used to identify a control group matched on age, BMI,
21 sex, and DM status. Patients were then matched using 1:1 nearest neighbor propensity
22 score (PS) matching. Balance was assessed by standardized mean differences, with an

1 acceptable threshold of 0.1. Annualized percentage BMD change at total hip was used
2 as the primary outcome. Normality testing (Shapiro Wilk) was performed, and
3 continuous variables were analyzed by Student t test or Wilcoxon rank sums test and
4 categorical variables were compared by Chi-square test. Linear regression was
5 performed on the primary outcome to detect the interaction effect between GLP-1 RA
6 and DM. The relationship between weight loss and BMD was assessed by Pearson
7 correlation. Two-sided P values <0.05 were considered to indicate statistical
8 significance. Statistical analysis was performed with SAS (9.4, SAS institute, United
9 States).

10

11 **Results:**

12 *Baseline characteristics*

13 Our study included 255 patients who initiated and used semaglutide or tirzepatide (GLP-
14 1 RA group) for a minimum of 6 months and 255 matched controls. The demographic
15 data for study subjects is summarized in Table 1. The mean age of the subjects was
16 63.9 ± 9.4 years. The majority were white, and 92% were women. The average baseline
17 BMI was 31.0 ± 5.6 kg/m². GLP-1 RA users and controls were of similar height, weight
18 and BMI at baseline. Nineteen percent of patients in the GLP-1 RA group received
19 medications such as glucocorticoids, aromatase inhibitors, or gonadotropin-releasing
20 hormone agonists/antagonists, with no significant difference compared to controls.
21 Within the GLP-1 RA group, 28% of individuals had comorbidities associated with
22 skeletal fragility, such as prior bariatric surgery, prior solid organ transplantation, primary

1 hyperparathyroidism, celiac disease, inflammatory bowel disease, or chronic kidney
2 disease. The prevalence of these conditions was comparable between the two groups.
3 The use of anti-osteoporotic agents—including bisphosphonates, hormone replacement
4 therapy, denosumab, teriparatide, abaloparatide, romosozumab, and raloxifene—did not
5 differ significantly between GLP-1 RA group and controls.

6 *Weight loss and GLP-1 RA use*

7 In the GLP-1 RA group, the majority of patients (84%) initiated treatment with
8 semaglutide, while 16% initiated with tirzepatide; 41 patients (16%) switched from
9 semaglutide to tirzepatide during the follow-up period. Overall, 76% of patients were
10 taking a low maintenance dose at the end of the study period. Patients in the high-dose
11 group had a significantly higher baseline BMI (32.9 ± 5.6 vs. 30.6 ± 5.6 , $p=0.01$), but the
12 percent weight loss was similar in the low-dose and high-dose subgroups. The median
13 time from GLP-1 RA initiation to follow-up DXA scan was 17 months. The median
14 percent weight reduction at follow-up was 5.3% (4 kg), and 32% of patients
15 achieved >10% weight loss. Among patients with more than 10% weight loss, the
16 duration of GLP-1 RA use, prevalence of DM, percent receiving high maintenance
17 doses, female sex, and age were similar to those without 10% weight loss. In the control
18 group, BMI was not significantly changed between the baseline and follow-up time
19 periods.

20 *BMD change and weight loss*

21 The median follow-up time between the two DXA scans was similar in the GLP-1 RA
22 and control groups, at approximately 2.8 years. Both groups demonstrated significant

1 declines in BMD at the total hip and femoral neck on follow-up DXA scans compared to
2 baseline, with the greatest annualized loss at the total hip (Table 2, Figure 1). The GLP-
3 1 RA group also experienced significant BMD loss at the lumbar spine, which was not
4 observed in the control group. In the GLP-1 RA group, weight loss was significantly
5 associated with BMD loss at the total hip ($r=0.32$, $p<0.01$) and at the femoral neck
6 ($r=0.17$, $p<0.01$), but not at the lumbar spine. When annualized percentage BMD
7 change was examined, weight loss remained significantly associated with total hip BMD
8 loss ($r = 0.26$, $p =0.04$), but not with BMD changes at femoral neck (Figure 2). Patients
9 who lost $>10\%$ of their body weight experienced greater total hip BMD loss compared
10 with those who lost $<10\%$ (-3.8% vs -1.9% , $p<0.01$). No significant differences in
11 annualized BMD at the total hip or femoral neck were noticed between the GLP-1 RA
12 group and control group, although patients in the GLP-1 RA group exhibited greater
13 annualized lumbar spine bone loss than controls (-0.5% vs. 0.6% , $p = 0.001$).

14 *Osteopenia, osteoporosis and trabecular bone score*

15 At baseline, within the GLP-1 RA group 56% of patients had osteopenia and 14% had
16 osteoporosis. At follow up, the prevalence of osteopenia and osteoporosis increased to
17 60% and 16% respectively. These findings were comparable to those seen in the control
18 group (Table 1). Baseline T-scores were -0.5 ± 1.5 at the lumbar spine, -1.1 ± 1.0 at the
19 femoral neck, -0.4 ± 1.1 at the total hip and -0.8 ± 1.3 at the forearm, respectively.
20 Trabecular bone scores were similar between the two groups at both baseline and
21 follow-up.

22 *Diabetes versus non-diabetes*

1 Among patients in the GLP-1 RA group, 3% had T1DM, 41% had T2DM, and 10%
2 required insulin use, all of which were similar to the control group. In both groups,
3 baseline BMD was highest in patients with T2DM, followed by those without DM, while
4 patients with T1DM had the lowest BMD across all sites. In both groups, the extent of
5 bone loss was similar between patients with and without DM (Table 3). Among patients
6 without DM, the GLP-1 RA group experienced greater annualized bone loss at the
7 lumbar spine and total hip (-0.55% versus 0.62% at lumbar spine, $p < 0.01$; -1% versus -
8 0.57% at total hip, $p = 0.04$). In contrast, among patients with DM, TH bone loss was
9 similar between the GLP-1 RA and control groups.

10 We conducted a subgroup analysis excluding patients on medications that
11 adversely affect bone, those with comorbidities potentially impacting bone health, and
12 those receiving osteoporosis treatment. This subgroup included 113 patients from the
13 GLP-1 RA group and 89 patients from the control group (Table 4). Among them, 60
14 patients in the GLP-1 RA group and 30 in the control group had DM. Baseline age and
15 BMI were similar in both groups. Among patients without DM (53 in the GLP-1 RA group
16 and 59 in the control group), significantly greater annualized total hip bone loss was
17 noticed in the GLP-1 RA group (-1.1% vs. -0.5%, $p = 0.02$, Figure 3). In contrast,
18 annualized total hip bone loss was comparable between the GLP-1 RA group and the
19 control group among patients with DM. Similar findings were noticed in analyses
20 restricted to patients with only T2DM. Linear regression model on annualized
21 percentage change in total hip BMD further confirmed that the effects of GLP-1 RA on
22 the outcome differed by DM status (estimated effect of interaction between GLP-1 RA
23 vs. DM=0.88, $p = 0.047$).

1 We also performed a subgroup analysis restricting to patients with class II obesity
2 or higher and found that the distinct effects of GLP-1 RA on TH BMD were even more
3 pronounced (Figure 3). Among patients with DM and class II obesity or higher, the
4 average annualized TH BMD change was 0.1% in the GLP-1 RA group versus -1.0% in
5 the control group ($p = 0.20$). In patients without DM and with class II obesity or higher,
6 the GLP-1 RA group experienced greater TH BMD loss than the control group (-2.2%
7 vs. -0.5%, $p=0.03$).

8 **Discussion:**

9 In this study, annualized bone loss at the total hip and femoral neck was similar
10 between the GLP-1 RA and control groups; however, the GLP-1 RA group experienced
11 greater annualized bone loss at the lumbar spine. In the GLP-1 RA group, weight loss
12 was significantly associated with bone loss at both the total hip and femoral neck. After
13 excluding patients receiving osteoporosis treatments and those with medications or
14 comorbidities known to affect bone metabolism, we found that patients without DM
15 treated with semaglutide or tirzepatide experienced significantly greater total hip bone
16 loss compared with controls and such effects were not found in those with DM.

17 Our study observed a median weight reduction of only 5.3% in the overall cohort
18 with a median follow up of 17 months, much smaller than the 14.9% to 22.5% reported
19 in clinical trials with semaglutide and tirzepatide (19-22). This is most likely due to
20 several factors. In our cohort, approximately three-quarters of participants were
21 receiving low maintenance doses. Prior studies have shown that weight loss is dose-
22 dependent(19-22). Notably, the 5% weight loss we observed is consistent with findings
23 from a recent meta-analysis of low-dose tirzepatide and a recent real-world study of

1 low-dose semaglutide (18,23). Our cohort also included patients primarily with class I
2 obesity and previous studies have found that patients with lower baseline BMIs tend to
3 have less weight loss(24,25). In addition, our cohort included 41% of patients with
4 T2DM and previous studies have shown that patients with T2DM tend to have less
5 weight loss than those without (14). Furthermore, the mean age of our study population
6 was 63.9 years, and prior studies have reported that participants over 65 years of age
7 receiving tirzepatide experienced numerically lower weight loss compared with the
8 overall study population (26).

9 Several studies have examined the effects of GLP-1 RA therapy on bone, but the
10 findings remain controversial. In our study, we found distinct effects of GLP-1 RA on
11 bone among patients with and without DM. Among patients without DM, we found that
12 patients taking GLP-1 RA experienced more substantial bone loss at the total hip
13 compared with the control group. This finding is consistent with two previous studies
14 that included more than 50 patients without DM and provided follow-up BMD
15 measurements(12,27), while other smaller studies on patients without DM were limited
16 by sample size or the absence of longitudinal BMD data (10,15-17). In a phase 2
17 randomized clinical trial, Hansen et al. demonstrated that 52 weeks of semaglutide
18 treatment in patients without DM but with osteopenia or prior fractures led to increased
19 bone resorption markers, lower lumbar spine and total hip areal BMD, and reduced tibial
20 volumetric BMD compared with placebo(12). Jensen et al. found that liraglutide
21 monotherapy resulted in greater reductions in hip and spine BMD than exercise alone,
22 despite comparable weight loss among adults aged 18–65 years without DM; this effect
23 was not observed when liraglutide was combined with exercise(27). The greater total

1 hip bone loss observed among patients without DM in the GLP-1 RA group was most
2 likely related to weight loss, as we identified a significant association between weight
3 loss and bone loss. This finding was similar to previous studies showing that total hip
4 BMD is particularly susceptible to weight loss regardless of method, including dietary
5 modification, exercise, and bariatric surgery(28-30). The hip may be especially
6 vulnerable because of its higher proportion of cortical bone and greater mechanical
7 unloading with weight reduction(31).

8 However, we did not identify such an effect in patients with DM, suggesting that
9 the skeletal impact of GLP-1 RA may differ based on DM status. Li et al. conducted a
10 24-week randomized controlled trial in 62 treatment-naive patients with DM receiving
11 exenatide, insulin, or pioglitazone, and found that patients in the exenatide group lost an
12 average of 4.7 kg without changes in lumbar spine or total hip BMD at follow up (32). In
13 another randomized controlled trial, Hygum reported no change in BMD among T2DM
14 patients treated with liraglutide 1.8 mg for 26 weeks despite a 4-kg weight loss, whereas
15 the placebo group showed a decline in total hip BMD from baseline(33). However, a
16 recent longitudinal study by Al Refaie et al. reported significant declines in lumbar spine
17 and total hip BMD after 12 months of liraglutide or semaglutide use among patients with
18 T2DM, though the absence of a matched control group limits interpretation, as the BMD
19 reduction may be related to aging, medication effects, or weight loss (34). A key
20 strength of our analysis was the inclusion of a matched control group with comparable
21 baseline BMI, age, sex, and BMD at all sites, which allowed us to demonstrate that
22 GLP-1 RA attenuated bone loss among patients with DM. The preservation of bone
23 among patients with DM receiving GLP-1 RA could be explained in several ways. In

1 vitro studies demonstrate that GLP-1 RAs exert bone-protective effects by promoting
2 osteoblast activity through RANK/OPG signaling, inhibiting osteoclastogenesis through
3 PI3K/AKT pathways, and attenuating advanced glycation end product-mediated
4 impairment of osteogenic proliferation and differentiation (35,36). In a mouse model of
5 T2DM, no differences in bone turnover markers or bone microstructural parameters
6 assessed by micro-CT were observed between mice treated with tirzepatide,
7 semaglutide, or controls, except for a lower cortical thickness in the semaglutide-treated
8 group(37). In addition, improvements in glycemic control associated with GLP-1 RA use
9 may partially mitigate the observed weight loss-related BMD loss. Finally, because
10 patients with T2DM, who comprised the majority of the DM group, often exhibit normal
11 or elevated BMD compared to those without DM, our neutral findings may suggest that
12 BMD is insufficient to assess skeletal health in this population(13). In T2DM, fracture
13 risk is driven largely by impaired bone quality rather than bone quantity, highlighting the
14 need for future studies to incorporate bone quality measures to better define the skeletal
15 effects of GLP-1 RA(16).

16 Our study has several limitations. This is a retrospective, single-center study
17 which inherently limits our ability to control follow-up intervals between DXA scans;
18 however, follow-up duration was comparable between groups, and annualized BMD
19 change was used as the primary outcome. We could not standardize medication doses,
20 and frequent switching between semaglutide and tirzepatide due to intolerance,
21 insurance issues, or drug shortages prevented a direct comparison between the two
22 medication. We did not assess HbA1c levels or other DM medications that could
23 potentially affect bone outcomes in patients with DM. While information on changes in

1 lean mass and total body mass would have been valuable, we had insufficient data for
2 whole-body composition scans, as these are often not covered by insurance. In
3 addition, lifestyle factors such as dietary calcium and vitamin D intake and physical
4 activity were not available. The study was conducted at a single academic institution,
5 limiting the study population's heterogeneity. The majority of participants had class I
6 obesity, however, we performed a subgroup analysis of patients with class II obesity or
7 higher and found that the distinct effect of GLP-1 RAs on total hip BMD change based
8 on DM status was more pronounced in those with more severe obesity. Because our
9 inclusion criteria required at least two DXA scans and routine osteoporosis screening
10 with DXA is not commonly performed in men, the study included a predominantly female
11 population. Our study also included a higher proportion of Caucasian patients in the
12 GLP-1 RA group than in the control group, which may reflect racial disparities in access
13 to GLP-1 RA. In addition, patients receiving osteoporosis treatment, medications known
14 to negatively affect bone, and comorbidities that may influence bone health were
15 included in the initial analysis to ensure adequate sample size for propensity score
16 matching without imposing excessive restrictions, although this could introduce residual
17 confounding. Therefore, we performed subgroup analyses excluding patients with these
18 factors, and the overall conclusions remained unchanged. These results may indicate
19 that inclusion of participants on bone-active medications did not materially affect our
20 conclusions. Finally, the relatively small cohort size and limited duration of follow-up
21 constrained our ability to assess fracture incidence.

22 In conclusion, patients receiving semaglutide or tirzepatide with modest weight
23 loss experienced similar bone loss during follow-up compared with age-, BMI-, sex-, and

1 DM-matched controls, with the greatest decline observed at the total hip. Among these
2 patients, weight loss was significantly associated with bone loss at the total hip and
3 femoral neck. Subgroup analyses revealed differences according to DM status: in
4 patients without DM treated with semaglutide or tirzepatide, annualized total hip bone
5 loss was significantly greater than in controls, whereas no such effect was observed in
6 patients with DM. Further prospective, controlled studies are warranted to confirm these
7 findings and guide clinical management.

9 Data Availability

10 De-identified data will be made available upon reasonable request.

11 References:

- 12 1. Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L,
13 Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-
14 Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana
15 RM, Arnlov J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S,
16 Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG,
17 Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B,
18 Esteghamati A, Feigin VL, Fernandes JC, Furst T, Gebrehiwot TT, Gold A, Gona PN, Goto A,
19 Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A,
20 Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim
21 YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez
22 AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST,
23 Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap
24 JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK,
25 Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M,
26 Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ,
27 Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabares-
28 Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R,
29 Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE,
30 Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z,
31 Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over
32 25 Years. *N Engl J Med*. 2017;377(1):13–27.

- 1 2. Collaboration NCDRF. Worldwide trends in underweight and obesity from 1990 to 2022: a
2 pooled analysis of 3663 population-representative studies with 222 million children,
3 adolescents, and adults. *Lancet*. 2024;403(10431):1027–1050.
- 4 3. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker SL. Projected
5 U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med*.
6 2019;381(25):2440–2450.
- 7 4. Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. *Nat Rev Drug Discov*. 2025.
- 8 5. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC,
9 Senyucel C, Dunn JP, Investigators S-T. Tirzepatide as Compared with Semaglutide for the
10 Treatment of Obesity. *N Engl J Med*. 2025;393(1):26–36.
- 11 6. Liu L, Rosen CJ. New Insights into Calorie Restriction Induced Bone Loss. *Endocrinol Metab*
12 *(Seoul)*. 2023;38(2):203–213.
- 13 7. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and
14 management. *Lancet Diabetes Endocrinol*. 2014;2(2):165–174.
- 15 8. Krez AN, Stein EM. The Skeletal Consequences of Bariatric Surgery. *Curr Osteoporos Rep*.
16 2020;18(3):262–272.
- 17 9. Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, Ma JH. Effects of GLP-1 Receptor Agonists on
18 Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
19 *Biomed Res Int*. 2021;2021:3361309.
- 20 10. Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, Jensen JE, Holst JJ,
21 Madsbad S, Torekov SS. GLP-1 Receptor Agonist Treatment Increases Bone Formation and
22 Prevents Bone Loss in Weight-Reduced Obese Women. *J Clin Endocrinol Metab*.
23 2015;100(8):2909–2917.
- 24 11. Moiz A, Filion KB, Toutouchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and
25 Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without
26 Diabetes : A Systematic Review of Randomized Controlled Trials. *Ann Intern Med*.
27 2025;178(2):199–217.
- 28 12. Hansen MS, Wolfel EM, Jeromdesella S, Moller JK, Ejersted C, Jorgensen NR, Eastell R, Hansen
29 SG, Frost M. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a
30 randomised, double-blinded, two-centre, phase 2 trial. *EClinicalMedicine*. 2024;72:102624.
- 31 13. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and
32 type 2 diabetes--a meta-analysis. *Osteoporos Int*. 2007;18(4):427–444.
- 33 14. Singh A, Singh AK, Singh R, Misra A. Comparative efficacy and safety of semaglutide 2.4 mg and
34 tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3
35 clinical trials. *Diabetes Metab Syndr*. 2025;19(3):103212.
- 36 15. Maddaloni E, D'Eon S, Hastings S, Tinsley LJ, Napoli N, Khamaisi M, Bouxsein ML, Fouda SMR,
37 Keenan HA. Bone health in subjects with type 1 diabetes for more than 50 years. *Acta Diabetol*.
38 2017;54(5):479–488.
- 39 16. Sacher SE, Hunt HB, Lekkala S, Lopez KA, Potts J, Heilbronner AK, Stein EM, Hernandez CJ,
40 Donnelly E. Distributions of Microdamage Are Altered Between Trabecular Rods and Plates in
41 Cancellous Bone From Men With Type 2 Diabetes Mellitus. *J Bone Miner Res*. 2022;37(4):740–
42 752.
- 43 17. Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-Year Weight Reduction With
44 Semaglutide or Liraglutide in Clinical Practice. *JAMA Netw Open*. 2024;7(9):e2433326.
- 45 18. Gasoyan H, Butsch WS, Schulte R, Casacchia NJ, Le P, Boyer CB, Griebeler ML, Burguera B,
46 Rothberg MB. Changes in weight and glycemic control following obesity treatment with
47 semaglutide or tirzepatide by discontinuation status. *Obesity (Silver Spring)*. 2025.

- 1 19. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B,
2 Bunck MC, Stefanski A, Investigators S-. Tirzepatide Once Weekly for the Treatment of Obesity. *N*
3 *Engl J Med*. 2022;387(3):205–216.
- 4 20. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM,
5 Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, Group SS.
6 Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*.
7 2021;384(11):989–1002.
- 8 21. Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J,
9 Shimomura I, Viljoen A, Wadden TA, Lingvay I, Group SS. Semaglutide 2.4 mg once a week in
10 adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind,
11 double-dummy, placebo-controlled, phase 3 trial. *Lancet*. 2021;397(10278):971–984.
- 12 22. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad
13 NN, Bunck MC, Benabbad I, Zhang XM, investigators S-. Tirzepatide once weekly for the
14 treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind,
15 randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10402):613–626.
- 16 23. Qin W, Yang J, Ni Y, Deng C, Ruan Q, Ruan J, Zhou P, Duan K. Efficacy and safety of once-weekly
17 tirzepatide for weight management compared to placebo: An updated systematic review and
18 meta-analysis including the latest SURMOUNT-2 trial. *Endocrine*. 2024;86(1):70–84.
- 19 24. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, Colhoun HM, Cercato C, Dicker D,
20 Horn DB, Hovingh GK, Jeppesen OK, Kokkinos A, Lincoff AM, Meyhofer SM, Oral TK, Plutzky J, van
21 Beek AP, Wilding JPH, Kushner RF. Long-term weight loss effects of semaglutide in obesity
22 without diabetes in the SELECT trial. *Nat Med*. 2024;30(7):2049–2057.
- 23 25. Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, Eng PC, Tan BYQ, Sattar N, Dalakoti M, Sia CH.
24 Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients
25 With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47
26 Randomized Controlled Trials. *Diabetes Care*. 2025;48(2):292–300.
- 27 26. Rasouli N, Wilding JPH, Kwan AYM, Paik JS, Sharma P, Peleshok J. Tirzepatide for Older Adults
28 with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.
29 *Diabetes Ther*. 2025;16(4):701–715.
- 30 27. Jensen SBK, Sorensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR, Janus C, Ternhamar T,
31 Stallknecht BM, Holst JJ, Jorgensen NR, Jensen JB, Madsbad S, Torekov SS. Bone Health After
32 Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary
33 Analysis of a Randomized Clinical Trial. *JAMA Netw Open*. 2024;7(6):e2416775.
- 34 28. Zibellini J, Seimon RV, Lee CM, Gibson AA, Hsu MS, Shapses SA, Nguyen TV, Sainsbury A. Does
35 Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic
36 Review and Meta-Analysis of Clinical Trials. *J Bone Miner Res*. 2015;30(12):2168–2178.
- 37 29. Chen X, Zhang J, Zhou Z. Changes in Bone Mineral Density After Weight Loss Due to Metabolic
38 Surgery or Lifestyle Intervention in Obese Patients. *Obes Surg*. 2021;31(3):1147–1157.
- 39 30. Beavers KM, Walkup MP, Weaver AA, Lenchik L, Kritchevsky SB, Nicklas BJ, Ambrosius WT, Stitzel
40 JD, Register TC, Shapses SA, Marsh AP, Rejeski WJ. Effect of Exercise Modality During Weight Loss
41 on Bone Health in Older Adults With Obesity and Cardiovascular Disease or Metabolic
42 Syndrome: A Randomized Controlled Trial. *J Bone Miner Res*. 2018;33(12):2140–2149.
- 43 31. Stein EM, Carrelli A, Young P, Bucovsky M, Zhang C, Schrope B, Bessler M, Zhou B, Wang J, Guo
44 XE, McMahon DJ, Silverberg SJ. Bariatric surgery results in cortical bone loss. *J Clin Endocrinol*
45 *Metab*. 2013;98(2):541–549.
- 46 32. Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, Zhu D, Weng J. Effect of exenatide, insulin and
47 pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. *Acta*
48 *Diabetol*. 2015;52(6):1083–1091.

- 1 33. Hygum K, Harslof T, Jorgensen NR, Rungby J, Pedersen SB, Langdahl BL. Bone resorption is
 2 unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial. *Bone*.
 3 2020;132:115197.
- 4 34. Al Refaie A, Baldassini L, Mondillo C, Ceccarelli E, Tarquini R, Gennari L, Gonnelli S, Caffarelli C.
 5 Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of
 6 Incretines? A 12 Months Longitudinal Study. *Calcif Tissue Int*. 2024;115(2):160–168.
- 7 35. Li Z, Li S, Wang N, Xue P, Li Y. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses
 8 osteoclastogenesis through the inhibition of NF-kappaB and MAPK pathways via GLP-1R. *Biomed*
 9 *Pharmacother*. 2020;130:110523.
- 10 36. Tian Y, Liu H, Bao X, Li Y. Semaglutide promotes the proliferation and osteogenic differentiation of
 11 bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/beta-catenin
 12 signaling pathway. *Front Pharmacol*. 2025;16:1539411.
- 13 37. Lv F, Cai X, Lin C, Yang W, Ji L. Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type
 14 2 Diabetic Mice. *Pharmaceuticals (Basel)*. 2024;17(12).

15 Tables

16 Table 1. Baseline characteristics of overall cohort

	GLP-1 RA (N=255)	Control (N=255)	P value
Age (years, Mean \pm SD)	63.7 \pm 9.5	64.3 \pm 9.4	0.58
Female, N (%)	234 (92%)	237 (93%)	0.62
Ethnicity, N (%)			0.74
Hispanic	32 (13%)	38 (15%)	
Non-Hispanic	183 (72%)	177 (69%)	
Decline	40 (16%)	40 (16%)	
Race, N (%)			<0.001
Caucasian	159 (64%)	111 (44%)	
African American	21 (8%)	56 (22%)	
Asian American	9 (4%)	10 (4%)	
Other	66 (26%)	78(31%)	
Baseline BMI (kg/m ² , Mean \pm SD)	31.0 \pm 5.6	30.5 \pm 5.68	0.22
Baseline Weight (kg, Mean \pm SD)	82.2 \pm 16.8	79.6 \pm 15.7	0.06
Diabetes Mellitus, N (%)	112 (44%)	91(35.7%)	0.06
T1DM, N (%)	7 (3%)	4 (2%)	0.34
T2DM, N (%)	105 (41%)	87(3%)	0.15
Medication with detrimental skeletal potential, N (%)	48 (19%)	56 (22%)	0.64
Baseline BMD			0.53
Normal	76 (30%)	72(28%)	
Osteopenia (N, %)	143 (56%)	154 (60%)	
Osteoporosis (N, %)	36 (14%)	29 (11%)	
Osteoporosis treatment, N (%)	69 (27%)	53 (21%)	0.10

17 GLP-1 RA, Glucagon-Like Peptide-1 Receptor Agonist; T1DM, type 1 diabetes mellitus;
 18 T2DM, type 2 diabetes mellitus; Medication affecting bone loss includes glucocorticoids,
 19 aromatase inhibitors, or gonadotropin-releasing hormone agonists/antagonists.

20

1 Table 2. Bone mineral density change, osteopenia and osteoporosis at follow up

	GLP-1 RA (N=255)	Control (N=255)	P value
Baseline LS BMD (g/cm ² , Mean ± SD)	1.12 ± 0.20	1.11 ± 0.20	0.63
LS BMD change (% , Mean ± SD)	-1.5 ± 7.1*	1.4 ± 8.6	0.001
Annualized LS BMD change (% , Mean ± SD)	-0.5 ± 3.4	0.6 ± 4.5	0.001
Baseline FN BMD (g/cm ² , Mean ± SD)	0.88 ± 0.15	0.89 ± 0.13	0.21
FN BMD change (% , Mean ± SD)	-1.6 ± 6.3*	-2.1 ± 8.3*	0.55
Annualized FN BMD change (% , Mean ± SD)	-0.6 ± 3.2	-0.8 ± 3.8	0.95
Baseline TH BMD (g/cm ² , Mean ± SD)	0.95 ± 0.15	0.95 ± 0.13	0.72
TH BMD change (% , Mean ± SD)	-2.5 ± 4.4*	-2.0 ± 3.9*	0.28
Annualized TH BMD change (% , Mean ± SD)	-0.9 ± 1.9	-0.7 ± 1.7	0.16

2
3 BMD, bone mineral density; FN, femoral neck; GLP-1 RA, Glucagon-Like Peptide-1 Receptor
4 Agonist; LS, lumbar spine; SD, standard deviation; * indicates a statistically significant
5 within-group difference compared with baseline

7 Table 3. Weight, BMI and bone mineral density change in patients with DM versus without
8 DM.

9 BMD, bone mineral density; FN, Femoral neck; GLP-1 RA, glucagon-like peptide-1 receptor

	GLP-1 RA (n=255)			Control (n=255)		
	DM (N=112)	Non-DM (N=143)	P-value	DM (N=91)	Non-DM (N=164)	P-value
Baseline weight (kg, Mean, SD)	80.0 (16.0)	83.7 (17.3)	0.16	78.0 (17.0)	80.2 (14.9)	0.07
Weight change (% , Mean, SD)	-5.5 (7.8)	-6.7 (9.0)	0.47	-1.5 (7.1)	0.4(6.4)	0.05
Baseline BMI (kg/m ² , Mean,SD)	30.6 (5.7)	31.6 (5.7)	0.17	30.2 (6.3)	30.6 (5.3)	0.22
BMI change (% , Mean,SD)	-5.5 (8.4)	-6.3 (9.2)	0.49	-0.6 (8.6)	0.8 (6.6)	0.06
Annualized LS BMD change (% , Mean, SD)	-0.5 (3.3)	-0.6 (3.4)	0.61	0.7 (3.3)	0.6 (5.0)	0.91
Annualized FN BMD change (% , Mean, SD)	-0.5 (2.6)	-0.6 (3.7)	0.49	-0.1 (2.8)	-0.6 (1.8)	0.16
Annualized TH BMD change (% , Mean, SD)	-0.6 (1.4)	-0.9 (1.4)	0.51	-1.1 (1.8)	-0.5 (1.2)	0.02

10 agonist; LS, lumbar spine; TH, total hip

12 Table 4. Weight, BMI and bone mineral density change in patients with DM versus without
13 DM after excluding confounding factors like comorbidities, osteoporosis medications, and
14 other medication with detrimental skeletal potential.


	DM			Non-DM		
	GLP-1 RA (N=60)	Control (N=30)	P-value	GLP-1 RA (N=53)	Control (N=59)	P-value
Baseline weight (kg, Mean, SD)	80.1 (15.7)	79.7 (20.8)	0.27	83.1 (14.3)	81.2 (15.4)	0.53
Weight change (% , Mean, SD)	-5.6(7.9)	-0.9 (6.3)	0.002	-5.4 (8.1)	0.0 (5.3)	<0.001
Baseline BMI (kg/m ² , Mean, SD)	31.3 (5.6)	31.2(7.6)	0.34	32.1 (5.4)	30.9 (5.6)	0.18
BMI change (% , Mean, SD)	-5.5 (8.6)	-1.0 (6.2)	0.006	-5.7 (8.1)	0.3 (5.8)	<0.001

Annualized LS BMD change (% Mean, SD)	-0.7 (2.3)	0.4 (2.6)	0.20	-0.1 (2.6)	0.4 (3.9)	0.26
Annualized FN BMD change (% Mean, SD)	-0.2 (2.3)	-0.9 (2.1)	0.16	-0.1 (2.8)	-0.6(1.8)	0.86
Annualized TH BMD change (% Mean, SD)	-0.6 (1.4)	-0.9 (1.4)	0.51	-1.1 (1.8)	-0.5 (1.2)	0.02

1 BMD, bone mineral density; FN, Femoral neck; DM, diabetes mellitus; GLP-1 RA, glucagon-
 2 like peptide-1 receptor agonist; LS, lumbar spine; TH, total hip

3


4 Figure 1. Annualized Percentage BMD change between GLP-1 RA group and control group.



5

6 Values in the bar chart are shown as mean ± standard error.

7 Figure 2. Association of weight loss and annualized percentage change total hip bone
 8 mineral density




9

10

1 BMD, bone mineral density; TH, total hip; Wt, weight;

2

3 Figure 3. Annualized total hip bone mineral density change in DM versus non-DM patients
4 after excluding confounding factors like comorbidities, osteoporosis medications, and
5 other medication with detrimental skeletal potential.



6

7 Values in the bar chart are shown as mean \pm standard error.